BioMarin Pharmaceutical

BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams

FDA · rare disease · 6 min

BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.

This Week’s Biopharma News: New Approvals, Appeals, and AI

FDA · 10 min

This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.

BioMarin's Study Success: Implications for Pharma Expansion

3 min

BioMarin Pharmaceutical has achieved a significant milestone in its latest study, potentially expanding the use of its top-selling medicine. This article explores the implications for the pharmaceutical industry.

BioMarin's Strategic Move: Voxzogo Label Expansion Insights

3 min

BioMarin Pharmaceutical aims to expand Voxzogo's label following a successful trial. This article analyzes the competitive implications for pharma teams.

BioMarin Seeks Approval for Voxzogo in Short Stature Indication

short stature · 3 min

BioMarin Pharmaceutical is pursuing further approval for Voxzogo to treat short stature. This article explores the implications for investors and pharma teams.